Movatterモバイル変換


[0]ホーム

URL:


US20240013149A1 - Method for repurposing ndc codes in a pharmaceutical database for allergens - Google Patents

Method for repurposing ndc codes in a pharmaceutical database for allergens
Download PDF

Info

Publication number
US20240013149A1
US20240013149A1US18/367,281US202318367281AUS2024013149A1US 20240013149 A1US20240013149 A1US 20240013149A1US 202318367281 AUS202318367281 AUS 202318367281AUS 2024013149 A1US2024013149 A1US 2024013149A1
Authority
US
United States
Prior art keywords
ndc
allergens
level
database
central control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US18/367,281
Inventor
James Strader
Jovan Hutton Pulitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roca Medical Ltd
Original Assignee
Roca Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/171,920external-prioritypatent/US20170024526A1/en
Application filed by Roca Medical LtdfiledCriticalRoca Medical Ltd
Priority to US18/367,281priorityCriticalpatent/US20240013149A1/en
Assigned to ROCA Medical Ltd.reassignmentROCA Medical Ltd.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: PULITZER, JOVAN HUTTON, STRADER, JAMES
Publication of US20240013149A1publicationCriticalpatent/US20240013149A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

A method for adjudicating reimbursement for allergens includes obtaining National Drug Codes (NDC's) for a plurality of allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.

Description

Claims (10)

What is claimed is:
1. A method for adjudicating reimbursement for allergens, the method comprising:
diluting a plurality of allergens, wherein each of the plurality of allergens is diluted by the steps of:
extracting a defined amount of concentrated allergen extract from a container of concentrated allergen extract and disposing it within a first one of a plurality of sterile containers containing a dilutant, to provide a first dilution level, wherein each of the plurality of sterile containers is associated with a different dilution level,
extracting a defined amount of diluted allergen from the first one of the sterile containers and disposing it within a second one of the sterile containers to provide a second dilution level, and
progressively extracting a defined amount of diluted allergens from a previous one of the sterile containers to a next thereof containing a dilutant to provide progressively more diluted levels until a last of the sterile containers containing a final dilution level, to provide a plurality of defined concentration levels of diluted allergens, and
obtaining, at a central control center, National Drug Codes (NDCs) for the plurality of allergens each at one of the plurality of defined concentration levels of diluted allergens, each NDC uniquely identifying a particular allergen as to its manufacture, the particular allergen, packaging, and a defined concentration level of the particular allergen, and further obtaining information as to a description of the particular allergen, the defined concentration level of the particular allergen, and manufacturer of the particular allergen;
determining, by the central control center, an Average Wholesale Price (AWP) for each of the allergens associated with one of the NDCs;
storing, in a central control database, the NDCs in association with an associated Average Wholesale Price (AWP) and associated information for NDC-carrying allergens, which associated information allows practitioners to determine from a diluted level and number of doses of one of the NDC-carrying allergens and a known dilution procedure how to translate back to an amount of a base concentrate of the one of the NDC-carrying allergens used to create the diluted level and number of doses;
accessing a third-party database accessible by a pharmacist and determining if any of the NDCs in the central control database are contained within the third-party database and, if not:
transferring NDCs not in the third-party database and that exist in the central control database for each of the allergens to the third-party database with the associated AWP and associated information for each of the allergens for each of the NDCs, and
uniquely associating each of the NDCs in the third-party database to the central control center for adjudication information; and
creating an adjudicating database at the central control center having defined benefits associated with reimbursable entities for each of the NDCs stored in the third-party database and in the central control database in association with the associated information for each of the NDC-carrying allergens.
2. The method ofclaim 1, wherein the base concentrate of the one of the NDC-carrying allergens is any concentration level that is too toxic for a patient to be exposed to.
3. The method ofclaim 1, and further comprising the step of a physician creating a script defining a desired diluted level and a number of doses of at least one of the NDC-carrying allergens.
4. The method ofclaim 3, wherein the script includes desired diluted levels to be included within each dose.
5. The method ofclaim 3, wherein diluting the plurality of allergens is performed by a pharmacist, and includes diluting the at least one of the NDC-carrying allergens to the desired diluted level and the number of doses defined by the script.
6. The method ofclaim 1, wherein the associated information includes a table of dilution levels of the one of the NDC-carrying allergens associated with a plurality of dilution procedures wherein each of the dilution levels defines the number of doses at the dilution level and, via the known dilution procedure, the amount of the base concentrate of the one of the NDC-carrying allergens required to yield the dilution level and the number of doses.
7. The method ofclaim 6, wherein each of the NDC-carrying allergens is defined as being able to be distributed in discrete quantities, each of the discrete quantities associated with a starting level of an NDC-carrying allergen and each of the discrete quantities adjudicatable.
8. The method ofclaim 1, further comprising determining, by the central control center, the associated AWP for each of the allergens associated with one of the NDCs based on the obtained information as to the description of the particular allergen, the defined concentration level of the particular allergen, and the manufacturer of the particular allergen.
9. The method ofclaim 1, further comprising:
generating a link in the third-party database associated with a particular NDC of one of the NDCs that directs to the adjudicating database to obtain information regarding reimbursable benefits from the central control center and enter the diluted level and the number of doses and a claim with the central control center for adjudication of the amount of the base concentrate of the NDC-carrying allergen of the one of the NDC's, and wherein the central control center is able to process any claim made by a pharmacist and reimburse the pharmacist accordingly for the amount of the base concentrate of the NDC-carrying allergen used to provide the diluted level and number of doses of the NDC-carrying allergen.
10. The method ofclaim 9, further comprising:
defining, based on the generated link in the third-party database, the central control center as an owner and a provider of the particular NDC, wherein the generated link causes the central control center to be associated with each of the NDC's for which a unique link is generated and causes the central control center to be automatically included in adjudication of the plurality of allergens.
US18/367,2812015-06-022023-09-12Method for repurposing ndc codes in a pharmaceutical database for allergensAbandonedUS20240013149A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US18/367,281US20240013149A1 (en)2015-06-022023-09-12Method for repurposing ndc codes in a pharmaceutical database for allergens

Applications Claiming Priority (8)

Application NumberPriority DateFiling DateTitle
US201562169785P2015-06-022015-06-02
US201562169787P2015-06-022015-06-02
US201562203819P2015-08-112015-08-11
US15/171,920US20170024526A1 (en)2015-06-022016-06-02Method for managing reimbursements for previously non database allergens
US201662349626P2016-06-132016-06-13
US15/235,067US10872313B2 (en)2015-06-022016-08-11Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US17/128,301US11755996B2 (en)2015-06-022020-12-21Method for repurposing NDC codes in a pharmaceutical database for allergens
US18/367,281US20240013149A1 (en)2015-06-022023-09-12Method for repurposing ndc codes in a pharmaceutical database for allergens

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US17/128,301ContinuationUS11755996B2 (en)2015-06-022020-12-21Method for repurposing NDC codes in a pharmaceutical database for allergens

Publications (1)

Publication NumberPublication Date
US20240013149A1true US20240013149A1 (en)2024-01-11

Family

ID=57588040

Family Applications (3)

Application NumberTitlePriority DateFiling Date
US15/235,067Active2037-07-01US10872313B2 (en)2014-04-112016-08-11Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US17/128,301Active2036-08-08US11755996B2 (en)2015-06-022020-12-21Method for repurposing NDC codes in a pharmaceutical database for allergens
US18/367,281AbandonedUS20240013149A1 (en)2015-06-022023-09-12Method for repurposing ndc codes in a pharmaceutical database for allergens

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
US15/235,067Active2037-07-01US10872313B2 (en)2014-04-112016-08-11Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US17/128,301Active2036-08-08US11755996B2 (en)2015-06-022020-12-21Method for repurposing NDC codes in a pharmaceutical database for allergens

Country Status (1)

CountryLink
US (3)US10872313B2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5013555A (en)*1988-05-051991-05-07Collins Amy L TAgent for desensitizing man and/or animals against an allergen
US20030065537A1 (en)*2001-08-312003-04-03Docusys, Inc.System and method for displaying drug information
US20110282690A1 (en)*2010-05-132011-11-17Rx Specialty Hub LlcProspective management process for medical benefit prescriptions
US8328082B1 (en)*2010-05-302012-12-11Crisi Medical Systems, Inc.Medication container encoding, verification, and identification
US20140316796A1 (en)*2013-04-192014-10-23Jazz PharmaceuticalsSystems, methods, and computer-readable media for limited distribution of specialty drug using a computer hub operating at a single access point
US20160231342A1 (en)*2014-10-172016-08-11Hob Biotech Group Suzhou Co., Ltd.Method for preparation of purified allergen positive control serum

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2888924A (en)1958-02-251959-06-02Russell P DunmireHypodermic syringes
US3400716A (en)1964-06-051968-09-10William H. SchultzMultiple dosage hypodermic syringe
US3300055A (en)1964-12-141967-01-24Joseph H RohrRack
US3882863A (en)1973-08-011975-05-13Survival TechnologyHypodermic injection device having cannula covered with resilient sheath
USD247822S (en)1976-03-291978-05-02Lincoln Laboratories, Inc.Support base and holder for use in loading antigenic materials on a multi-applicator skin testing device
US4085782A (en)1976-05-241978-04-25Carlson Harold WVaccine and medicament dispensing system
US4195734A (en)1978-11-061980-04-01Boner John OApparatus for transporting medications or the like
US4292979A (en)1979-04-091981-10-06Inglefield Jr Joseph TAllergy testing apparatus
US4405047A (en)1981-07-221983-09-20Sterling Drug, Inc.Unit package for poultry vaccination
US4523679A (en)1984-03-051985-06-18Sterling Drug Inc.Pre-sterilized medical procedure kit packages
US4522302A (en)1984-03-051985-06-11Sterling Drug Inc.Pre-sterilized medical procedure kit packages
US4666441A (en)1985-12-171987-05-19Ciba-Geigy CorporationMulticompartmentalized transdermal patches
US4657138A (en)1986-04-111987-04-14Watson Frank KCarrying case for insulin syringes
US4915697A (en)1988-03-161990-04-10Dupont FrankHypodermic needle assembly
US4976351A (en)1989-06-011990-12-11PharmedixKit for distributing pharmaceutical products
CA2158159A1 (en)1993-05-051994-11-10David F. NegrottiModular laboratory equipment and coupling system
FR2715071B1 (en)1994-01-171996-03-01Aguettant Lab Automatic drug injector.
US5647371A (en)1995-04-121997-07-15Greer Laboratories, Inc.Skin testing device loading method
US20030078223A1 (en)1996-01-302003-04-24Eyal RazCompositions and methods for modulating an immune response
SE513475C2 (en)1996-11-222000-09-18Peridoc Ab Hudsticktestkit
US5911252A (en)1997-04-291999-06-15Cassel; DouglasAutomated syringe filling system for radiographic contrast agents and other injectable substances
US20050101905A1 (en)1997-09-032005-05-12Safer Sleep LimitedCoding of syringes to monitor their use
SE9803662D0 (en)1998-10-261998-10-26Pharmacia & Upjohn Ab autoinjector
US6569123B2 (en)1999-10-142003-05-27Becton, Dickinson And CompanyPrefillable intradermal injector
AU2001237471A1 (en)2000-02-152001-08-27Finnish Immunotechnology LtdImmunochemical methods
US7426476B2 (en)2000-03-272008-09-16Whittier Group Inc.System and method for automated prescription management
CA2407074A1 (en)2000-04-212001-11-01Jukka HartikkaCompositions and methods for in vivo delivery of polynucleotide-based therapeutics
AU2001290528A1 (en)2000-08-102002-02-18Baxa CorporationMethod, system, and apparatus for handling, labeling, filling, and capping syringes
US6488937B1 (en)2000-08-232002-12-03William SmitsAllergy treatment method using a rapid immunotherapy protocol
US6773695B2 (en)2000-10-052004-08-10Mannkind CorporationModulation of allergic response
EP1236644B1 (en)2001-02-282007-01-03Grifols, S.A.Apparatus for filling containers for pharmaceutical uses and the like
EP1377299A4 (en)2001-03-192009-11-11Intercell Usa Inc TRANSCUTANEOUS IMMUNOSTIMULATION
US20060153882A1 (en)2001-05-292006-07-13Emile LoriaAnti-allergic pharmaceutical composition containing at least one allergen and at least on antihistamine compound
US6779665B2 (en)2001-08-292004-08-24Henry BolanosGenealogy storage kit
DK2221076T3 (en)2001-11-092013-05-13Alza Corp Pneumatically operated auto injector
CA2465901C (en)2001-11-092010-10-26Pedro De La SernaCollapsible syringe cartridge
DE60229979D1 (en)2001-12-052009-01-02Circassia Ltd
US9072543B2 (en)2002-05-312015-07-07Vidacare LLCVascular access kits and methods
CN102145774B (en)2003-01-282013-08-21因斯蒂尔医学技术有限公司Method for filling the vial
US7698019B2 (en)2003-11-032010-04-13Tech Pharmacy Services, Inc.System and software of enhanced pharmaceutical operations in long-term care facilities and related methods
GB0326439D0 (en)2003-11-132003-12-17Imp College Innovations LtdMethods
US7857138B2 (en)2003-12-022010-12-28Mary Darlene TempleApparatus and method for delivery of medication
CA2554337A1 (en)2004-02-062005-08-25Greer Laboratories, Inc.Methods and compositions for dosing of allergens
DE202004005010U1 (en)2004-03-302004-06-17Aea Technology Qsa Gmbh Packaging for radioactive materials
US20060020514A1 (en)2004-07-232006-01-26Paul YeredMethod and system for aggregating multiple prescription claims
US7398802B2 (en)2004-09-022008-07-15Baker James WSystem for dispensing biological fluids
US7297136B2 (en)2004-12-062007-11-20Wyrick Ronald EMedicine injection devices and methods
WO2006079064A1 (en)2005-01-242006-07-27Antares Pharma, Inc.Prefilled needle assisted jet injector
US7438218B2 (en)2005-02-282008-10-21Per-Se TechnologiesSystems and methods for pharmacy reimbursement claim resubmission
EP1956985A2 (en)2005-11-232008-08-20Universität ZürichAllergy treatment by epicutaneous allergen administration
US20070142786A1 (en)2005-12-162007-06-21Lampropoulos Fred PSystem with color-coded medical syringes and basins
US8251947B2 (en)2006-05-032012-08-28Antares Pharma, Inc.Two-stage reconstituting injector
US7806265B2 (en)2006-07-122010-10-05Mobius Therapeutics, LlcApparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
US8579856B2 (en)2007-05-162013-11-12Mystic Pharmaceuticals, Inc.Unit dose drug delivery platform
US7918830B2 (en)2007-12-032011-04-05Pharmedium Services, LlcSafety device for drug delivery devices and containers
FR2924349B1 (en)2007-12-032010-01-01Dbv Tech ALLERGEN DISENSIBILITY METHOD
US20110233079A1 (en)2009-06-302011-09-29Macinnes Susan EMedical Kit, Packaging System, Instruction Insert, and Associated Methods
US8506966B2 (en)2008-02-222013-08-13Novartis AgAdjuvanted influenza vaccines for pediatric use
US20090255843A1 (en)2008-04-112009-10-15Andrew Charles KrakowskiSystems and kits for treatment methods
US8802370B2 (en)2008-05-232014-08-12Strand Diagnostics, LlcMethod and apparatus to minimize diagnostic and other errors due to transposition of biological specimens among subjects
EP2147674A1 (en)2008-07-242010-01-27Besins HealthcareTransdermal pharmaceutical compositions comprising danazol
KR101825697B1 (en)2009-02-102018-02-05노파르티스 아게Influenza vaccines with reduced amounts of squalene
US8617487B2 (en)2009-03-252013-12-31Venture Lending & Leasing Vi, Inc.Saliva sample collection systems
US9289355B2 (en)2009-04-032016-03-22Sapa-Ip, LlcDilution kit and method
US8459679B2 (en)2009-07-212013-06-11Huffy CorporationPivot mechanism for scooters, tricycles and the like
RU2575599C2 (en)2010-03-122016-02-20Мериал ЛимитедRecombinant vaccines against bluetongue virus, their use
US20110229517A1 (en)2010-03-172011-09-22Sanofi Pasteur, Ltd.System and process for producing multi-component biopharmaceuticals
EP2575832B1 (en)2010-06-032017-07-26ALK-Abelló A/SPharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
WO2011159714A2 (en)2010-06-142011-12-22Duncan David RMedication infusion kit
US20120000592A1 (en)2010-07-012012-01-05Sagent Pharmaceuticals, Inc.Label, labeling system and method of labeling for containers for drug products
WO2012007843A2 (en)2010-07-122012-01-19Foamix Ltd.Apparatus and method for releasing a unit dose of content from a container
CN103547287A (en)2010-10-152014-01-29爱尔开-阿贝优公司Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
US9139316B2 (en)2010-12-292015-09-22Cardinal Health 414, LlcClosed vial fill system for aseptic dispensing
US20120185276A1 (en)2011-01-182012-07-19Reshma ShahSystem for Medication Information and Storage
KR20190090055A (en)2011-01-282019-07-31사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
ES2681698T3 (en)2011-03-022018-09-14Glaxosmithkline Biologicals Sa Combination vaccines with lower doses of antigen and / or adjuvant
US20130102772A1 (en)2011-07-152013-04-25Cardinal Health 414, LlcSystems, methods and devices for producing, manufacturing and control of radiopharmaceuticals-full
JP5748624B2 (en)2011-09-142015-07-15株式会社トーショー Chemical management system
CA2852857A1 (en)2011-10-202013-04-25Novartis AgAdjuvanted influenza b virus vaccines for pediatric priming
EP2626082A1 (en)2012-02-132013-08-14DBV TechnologiesMethod of preventing allergies
ITVI20120215A1 (en)2012-08-302014-03-01Fedegari Autoclavi STRUCTURE FOR PACKAGING COMPONENTS FOR PHARMACEUTICAL CONTAINERS
ITRM20120592A1 (en)2012-11-262014-05-27Mauro Pepe SAFETY KIT FOR THE TREATMENT OF BIOLOGICAL MATERIAL.
US20140276196A1 (en)2013-03-152014-09-18Allergy Devices, Inc.System and Method for Allergy Testing
US20140276197A1 (en)2013-03-152014-09-18Greer Laboratories, Inc.Apparatus and method for determining treatment endpoints for allergen testing
US9078983B2 (en)2013-08-192015-07-14Becton, Dickinson And CompanyPrefilled safety pen needle
US9592180B2 (en)2014-01-302017-03-14Pharmaceutical Design, LlcMethod and device for treating allergic reactions and difficult-to-manage respiratory diseases
US20150290129A1 (en)2014-04-112015-10-15ROCA Medical Ltd.Method for delivery of immunomodulators to a patient
ES2551809B1 (en)2014-05-212016-05-17Kiro Robotics Sl Intravenous substance preparation machine
US20150342514A1 (en)2014-05-292015-12-03Kenneth EastonSystem and method for multiple allergen testing
US10357267B2 (en)2014-07-302019-07-23ENT Solutions Group LLCSinus anesthesia kit
US20160042150A1 (en)2014-08-112016-02-11Joseph MoloughneyIntelligent Pill Dispenser With Remote Scheduling And Monitoring
US20160103975A1 (en)2014-10-102016-04-14Envision Pharmaceutical Holdings LLCPre-verification of prescriptions
AU2015343046B2 (en)2014-11-072020-05-28North Carolina State UniversityMethods and compositions for attenuating allergenicity in protein products
US10149904B2 (en)2015-02-202018-12-11The Board Of Trusteees Of The Leland Stanford Junior UniversityMixed allergen compositions and methods for using the same
US10548974B2 (en)2015-06-022020-02-04ROCA Medical Ltd.Therapeutic treatment kit for allergies based on DNA profiles
US20160362205A1 (en)2015-06-022016-12-15ROCA Medical Ltd.Use of autoinjector for distributing antigens to the public
US10369215B2 (en)2015-06-022019-08-06ROCA Medical Ltd.Predilution sets for distributing antigens
US10702203B2 (en)2016-02-042020-07-07ROCA Medical Ltd.Prick test single use sterile vial and method
WO2017134532A1 (en)2016-02-042017-08-10ROCA Medical Ltd.Regional allergen testing kit and method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5013555A (en)*1988-05-051991-05-07Collins Amy L TAgent for desensitizing man and/or animals against an allergen
US20030065537A1 (en)*2001-08-312003-04-03Docusys, Inc.System and method for displaying drug information
US20110282690A1 (en)*2010-05-132011-11-17Rx Specialty Hub LlcProspective management process for medical benefit prescriptions
US8328082B1 (en)*2010-05-302012-12-11Crisi Medical Systems, Inc.Medication container encoding, verification, and identification
US20140316796A1 (en)*2013-04-192014-10-23Jazz PharmaceuticalsSystems, methods, and computer-readable media for limited distribution of specialty drug using a computer hub operating at a single access point
US20160231342A1 (en)*2014-10-172016-08-11Hob Biotech Group Suzhou Co., Ltd.Method for preparation of purified allergen positive control serum

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Greg Plunkett, Stability of allergen extracts used in skin testing and immunotherapy, 2008, Current Opinion in Otolaryngology & Head and Neck Surgery, 16:285–291 (Year: 2008)*

Also Published As

Publication numberPublication date
US20160371445A1 (en)2016-12-22
US10872313B2 (en)2020-12-22
US11755996B2 (en)2023-09-12
US20210287174A1 (en)2021-09-16

Similar Documents

PublicationPublication DateTitle
US20230005581A1 (en)Individually customized allergy cream for individual patient profile
US10813992B2 (en)Predilution sets for distributing antigens
Durfee et al.ASPEN standards for nutrition support: home and alternate site care
Falit et al.Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers
US20230149539A1 (en)Therapeutic treatment kit for allergies based on dna profiles
Kale et al.A comparison of pharmacy dispensing channel use and adherence to specialty drugs among Medicare Part D beneficiaries
US12097294B2 (en)Transdermal patch with separated regions for delivery of immunomodulators
US20160362205A1 (en)Use of autoinjector for distributing antigens to the public
US11755996B2 (en)Method for repurposing NDC codes in a pharmaceutical database for allergens
WO2017025812A1 (en)Method for repurposing ndc codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US11004552B2 (en)Method and apparatus for completing prescription for allergen cocktail with patch
WO2017060774A1 (en)Individually customized allergy cream for individual patient profile
WO2019069114A1 (en)Individually customized allergy cream for individual patient profile
WO2017216633A1 (en)Method and apparatus for completing prescription for allergen cocktail with patch
Chand et al.Brown, white and blue bagging in special pharmacy: An emerging trend to minimize medication error
ThompsonSublingual immunotherapy approved for grass pollen allergies
Berry et al.Evaluation of an outpatient pharmacist consult service at a large academic medical center
TankersleyCurrent concepts in optimized construction of allergen immunotherapy vaccines: Practical implications.
Sanborn et al.The safety of intravenous drug delivery systems: update on current issues since the 1999 consensus development conference
Chanthapasa et al.Situation of adopting the automated medication pre-dispensing machine in public hospitals in Thailand
PricingREPORT TO CONGRESS
US20170024526A1 (en)Method for managing reimbursements for previously non database allergens
Rowe et al.Self-injection experiences among transgender people on injectable gender-affirming hormone therapy: a narrative review
Sumida et al.The Daniel K. Inouye College of Pharmacy Scripts: Prescription Drug Pricing
Khan et al.A study on the present status of Pharmacy and Pharmacists in health care sector.

Legal Events

DateCodeTitleDescription
STPPInformation on status: patent application and granting procedure in general

Free format text:DOCKETED NEW CASE - READY FOR EXAMINATION

ASAssignment

Owner name:ROCA MEDICAL LTD., UNITED KINGDOM

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STRADER, JAMES;PULITZER, JOVAN HUTTON;REEL/FRAME:066067/0154

Effective date:20160817

STPPInformation on status: patent application and granting procedure in general

Free format text:NON FINAL ACTION MAILED

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp